psychedelics

NIH Workshop on Psychedelics as Therapeutics

Washington, D.C., United States, 12 January 2022

To learn what does Science can tell about the gaps, challenges, and opportunities on psychedelics as therapeutics, the US National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) will host a virtual and free workshop on January 12 and 13, 2022.

NIH Workshop on Psychedelics as Therapeutics: Gaps, Challenges and Opportunities

Washington DC, United States, 12 January 2022

Register now: https://www.eventbrite.com/e/workshop-on-psychedelics-as-therapeutics-gaps-challenges-opportunities-tickets-216497739567?keep_tld=1

The NIH Workshop on Psychedelics as Therapeutics is sponsored by the National Institute of Mental Health,

Interdisciplinary Conference on Psychedelic Research

Haarlem, Netherlands, 24 April 2020

The fourth edition of the Interdisciplinary Conference on Psychedelic Research. ICPR 2020 takes place from Friday 24 to Sunday 26 April 2020 in Haarlem, The Netherlands.

Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study

Geoffrey E. Noller, Chris M. Frampton & Berra Yazar-Klosinski (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study, The American Journal of Drug and Alcohol Abuse, 44:1, 37-46, DOI: 10.1080/00952990.2017.1310218

Publication Date

12 April 2017

ABSTRACT

Background: The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes.

Read more about Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study